FPT-SOFTWARE
31.7.2024 04:01:26 CEST | Business Wire | Press release
Global leading IT company FPT Software announced that its Chief Artificial Intelligence Officer, Dr. Nguyen Xuan Phong, has been listed on the 2024-2025 Artificial Intelligence 150 (AI150) list by Constellation Research, recognizing leaders pioneering AI transformation efforts around the globe. The Chief AI Officer is the only executive from a Southeast Asian enterprise to be named to this elite list.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240730156983/en/
(Graphic: Business Wire)
2024-2025 Artificial Intelligence 150 (AI150) is an inaugural initiative by Constellation Research, a technology research and advisory firm based in Silicon Valley and one of the world’s leaders in digital transformation and disruptive technology consulting. The AI150 celebrates top global executives leading AI transformation efforts globally, across multiple industries, and in various roles including Chief AI Officer, Chief Digital Officer, Chief Technology Officer, and Chief Executive Officer.
The selection process lasts six months, from nomination by industry leaders to extensive reference checks for real projects, leadership, mentorship abilities, and standing among colleagues and peer groups. Each leader on the AI150 demonstrates a comprehensive understanding of how the world is responding to artificial intelligence and how new technologies can be leveraged for future innovation.
The accolade is a testament to Dr. Nguyen Xuan Phong and FPT Software’s commitment to being a pioneer, practitioner, and advocate for the acceleration of Intelligence Transformation while using AI to address key business and technology challenges of global enterprises. Others featured in the 2024-2025 list include executives from global technology leaders like SAP, Adobe, Google, Intel, Facebook, and Microsoft, as well as Fortune 500 enterprises such as Ford Motor, United Airlines, TotalEnergies, Merck, and Schneider Electric.
FPT Software and its parent company, FPT Corporation, have over a decade of experience in the research and development of AI solutions since the establishment of its first AI Research Lab in 2019, serving as a comprehensive research, development, and learning facility for 20,000 tech personnel. In his role, Dr. Nguyen Xuan Phong heads a robust global AI Center that drives AI research and industrial application for FPT Software’s global clients, strategizing AI integration, fostering innovation, boosting productivity, and ensuring ethical AI practices. He played an instrumental role in FPT Corporation’s global partnerships with leading AI players such as NVIDIA, Mila, Landing AI, AITOMATIC, and the recent founding membership of the AI Alliance led by IBM and Meta.
“At FPT Software, we believe AI is not just about algorithms; it’s about transforming organizations, industries, and people’s lives. We are committed to expanding our AI ecosystems and embedding AI and Generative AI into all of our solutions and services, as this technology will fundamentally transform everything in business and our society,” said Dr. Nguyen Xuan Phong. “It is my pleasure to be recognized in this esteemed list, and I look forward to engaging with Constellation Research and the AI150 community to participate in global conversations and research studies on AI and business transformation.”
“In the Age of AI, we can expect AI to be infused in every part of the business. This rapidly evolving field has pioneers, policy shapers, and practitioners that will transform industries,” noted R “Ray” Wang, founder and CEO at Constellation Research. “The AI150 is our attempt of identifying a small slice of the innovators and change agents that are making substantial contributions to the advancement of this revolution.”
In addition to his work with FPT Software, Dr. Nguyen Xuan Phong is a decorated scholar with a PhD/EngD from the University of Tokyo, majoring in AI. He also made significant contributions to AI research at Hitachi in Japan and the Mila, Quebec AI Institute in Canada.
The full listing can be found here: Artificial Intelligence 150 2024 - 2025 | Constellation Research Inc.
About FPT Software
FPT Software, a subsidiary of FPT Corporation, is a global technology and IT services provider headquartered in Vietnam, with $1 billion in revenue (2023) and over 30,000 employees in 30 countries.
The company champions complex business opportunities and challenges with its world-class services in Advanced Analytics, AI, Digital Platforms, Cloud, Hyperautomation, IoT, Low-code, and so on. It has partnered with over 1,100 clients worldwide, nearly 100 of which are Fortune Global 500 companies in Aviation, Automotive, Banking, Financial Services and Insurance, Healthcare, Logistics, Manufacturing, Utilities, and more. For more information, please visit https://fptsoftware.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730156983/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom